An adenosine analog (IB-MECA) inhibits anchorage-dependent cell growth of various human breast cancer cell lines
- PMID: 15147729
- DOI: 10.1016/j.biocel.2003.12.001
An adenosine analog (IB-MECA) inhibits anchorage-dependent cell growth of various human breast cancer cell lines
Abstract
A3 adenosine receptor agonists have been reported to influence cell death and survival. Here we report the effects of an A3 adenosine receptor agonist, IB-MECA, on the cell growth of human breast cancer cell lines, MCF-7 (estrogen receptor positive) and MDA-MB468 (estrogen receptor negative). Therefore, this study was aimed to investigate the expression and possible action of A3 receptor in the human breast cancer cell lines. IB-MECA, at 1-100 microM, resulted in a significant cell growth inhibition (P < 0.05) which reached the maximum at 48 h, in the cell lines. In both cell lines, agonist-induced effects were antagonized by pretreatment with a selective A3 adenosine receptor antagonist, MRS1220. Using RT-PCR method, further confirmation was provided by the presence of mRNA of A3 receptor in the cells. In addition, IB-MECA was able to inhibit forskolin-stimulated cAMP levels, which indicate the functional form of A3 receptor on the cell surface of these breast cancer cell lines. These results suggest that the inhibitory effect of IB-MECA on the growth of human breast cancer cell lines is mediated through activation of A3 adenosine receptor.
Similar articles
-
An adenosine analogue, IB-MECA, down-regulates estrogen receptor alpha and suppresses human breast cancer cell proliferation.Cancer Res. 2003 Oct 1;63(19):6413-23. Cancer Res. 2003. PMID: 14559831
-
Inhibition of cell proliferation through cell cycle arrest and apoptosis by thio-Cl-IB-MECA, a novel A3 adenosine receptor agonist, in human lung cancer cells.Cancer Lett. 2008 Jun 18;264(2):309-15. doi: 10.1016/j.canlet.2008.01.037. Epub 2008 Mar 5. Cancer Lett. 2008. PMID: 18321638
-
Estrogen up-regulates neuropeptide Y Y1 receptor expression in a human breast cancer cell line.Cancer Res. 2006 Apr 1;66(7):3706-14. doi: 10.1158/0008-5472.CAN-05-2744. Cancer Res. 2006. PMID: 16585197
-
IB-MECA and cardioprotection.Cardiovasc Drug Rev. 2006 Fall-Winter;24(3-4):227-38. doi: 10.1111/j.1527-3466.2006.00227.x. Cardiovasc Drug Rev. 2006. PMID: 17214599 Review.
-
Differential effect of adenosine on tumor and normal cell growth: focus on the A3 adenosine receptor.J Cell Physiol. 2001 Jan;186(1):19-23. doi: 10.1002/1097-4652(200101)186:1<19::AID-JCP1011>3.0.CO;2-3. J Cell Physiol. 2001. PMID: 11147810 Review.
Cited by
-
Antiproliferative effects of selective adenosine receptor agonists and antagonists on human lymphocytes: evidence for receptor-independent mechanisms.Purinergic Signal. 2013 Sep;9(3):351-65. doi: 10.1007/s11302-013-9354-7. Epub 2013 Jan 29. Purinergic Signal. 2013. PMID: 23359122 Free PMC article.
-
Human breast cancer cell line MDA-MB-231 expresses endogenous A2B adenosine receptors mediating a Ca2+ signal.Br J Pharmacol. 2005 May;145(2):211-8. doi: 10.1038/sj.bjp.0706180. Br J Pharmacol. 2005. PMID: 15753948 Free PMC article.
-
Synthetic Small-Molecule Ligands Targeted to Adenosine Receptors: Is There Potential Towards Ischemic Heart Disease?Cells. 2025 Aug 7;14(15):1219. doi: 10.3390/cells14151219. Cells. 2025. PMID: 40801651 Free PMC article. Review.
-
Autocrine and paracrine purinergic signaling in the most lethal types of cancer.Purinergic Signal. 2021 Sep;17(3):345-370. doi: 10.1007/s11302-021-09785-8. Epub 2021 May 12. Purinergic Signal. 2021. PMID: 33982134 Free PMC article. Review.
-
Molecular mechanisms of A3 adenosine receptor-induced G1 cell cycle arrest and apoptosis in androgen-dependent and independent prostate cancer cell lines: involvement of intrinsic pathway.J Cancer Res Clin Oncol. 2011 Oct;137(10):1511-23. doi: 10.1007/s00432-011-1031-z. Epub 2011 Aug 10. J Cancer Res Clin Oncol. 2011. PMID: 21830157 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical